Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04393090
Other study ID # CAN-17-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 2016
Est. completion date May 2017

Study information

Verified date May 2020
Source Cankado Service GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Since internet usage as a complementing element in cancer care is becoming more and more important in oncological routine we launched My-eStEPs (eHealth Strategy for Elderly Patients with Multiple Myeloma) to investigate how specifically elderly patients and their Healthcare Professionals (HCPs) adopt electronic Health (eHealth) support during outpatient treatment. The purpose of this project is to explore how eHealth support influences patients' interaction with their HCPs and how both can benefit from this.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- multiple myeloma patients

- treated by oral IMiDs

Exclusion Criteria:

-

Study Design


Related Conditions & MeSH terms


Intervention

Other:
eHealth platform CANKADO
The patients were asked to use the open eHealth platform CANKADO as a digital supporting tool.

Locations

Country Name City State
Germany Hämato-Onkologische Schwerpunktpraxis Aschaffenburg
Germany St.-Antonius-Hospital Eschweiler
Germany Praxis am Albertinen- Krankenhaus Hamburg
Germany Institut für Versorgungsforschung in der Onkologie GbR Koblenz
Germany Onkologie-Köln, Köln
Germany Gemeinschaftspraxis für Hämatologie und Onkologie Langen
Germany Praxis Dr. med. Peter Ehscheidt, Facharzt für Innere Medizin, Hämatologie, Onkologie, Medikamentöse Tumortherapie und Palliativmedizin Neuwied
Germany Medicum Wiesbaden

Sponsors (1)

Lead Sponsor Collaborator
Cankado Service GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of patient's internet use Evaluated in the following criteria: daily, at least once per week, at least once per month, less than once per month 3 months
Primary Purpose of patient's internet use Evaluated in the following criteria: news, online-banking, information collection about products, health-related topics, software downloads, dictionaries 3 months
Primary Patient's internet use for health-related topics Evaluated in the following criteria: does the patient use the internet for health-related topics and if yes, for what exactly 3 months
Primary Patient's technical equipment The presence of following equipment was evaluated: fixed network telephone, smartphone, internet-enabled computer, notebook, laptop, iPad and tablet ownership. 3 months
Primary eHealth usage satisfaction By a structured interview with the patients about their user satisfaction (graded between 1 (best) and 5 (worst)) 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1